Spinal cord hypermetabolism extends to skeletal muscle in amyotrophic lateral sclerosis: a computational approach to [18F]-fluorodeoxyglucose PET/CT images

EJNMMI Research

Table 1 FDG uptake data in ALS patients and control subjects

		Average	SD	Median	First quartile	Third quartile	IQR	p value
Spinal cord N-SUV	ALS patients	0.76	0.2	0.74	0.59	0.86	0.27	p < 0.05
Spinal cord N-SUV	Control subjects	0.66	0.12	0.65	0.59	0.79	0.20	p < 0.05
Cervical spinal cord N-SUV	ALS patients	0.96	0.3	0.94	0.74	1.15	0.41	p < 0.01
Cervical spinal cord N-SUV	Control subjects	0.73	0.2	0.70	0.64	0.96	0.32	p < 0.01
Dorsal spinal cord N-SUV	ALS patients	0.69	0.22	0.65	0.53	0.79	0.26	p = ns
Dorsal spinal cord N-SUV	Control subjects	0.64	0.11	0.66	0.25	0.40	0.15	p = ns
Brodmann Area 4	ALS patients	5.59	1.3	5.03	4.75	6.48	1.73	p < 0.01
Brodmann Area 4	Control subjects	6.67	0.3	6.3	6.29	7.18	0.89	p < 0.01
Whole brain cortex	ALS patients	5.11	1.3	5.08	4.52	6.54	2.02	p < 0.01
Whole brain cortex	Control subjects	5.95	0.2	5.98	5.64	6.41	0.77	p < 0.01
Psoas muscle	ALS patients	0.45	0.19	0.43	0.36	0.55	0.19	p < 0.01
Psoas muscle	Control subjects	0.29	0.09	0.28	0.23	0.35	0.12	p < 0.01